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Summary objective To assess the efﬁcacy of antimalarial treatment and molecular markers of Plasmodium
falciparum resistance in the Chittagong Hill Tracts of Bangladesh.
methods A total of 203 patients infected with P. falciparum were treated with quinine 3 days
plus sulphadoxine/pyrimethamine (SP) combination therapy, and followed up during a 4-week period.
Blood samples collected before treatment were genotyped for parasite mutations related to chloroquine
(pfcrt and pfmdr1 genes) or SP resistance (dhfr and dhps).
results Of 186 patients who completed follow-up, 32 patients (17.2%) failed to clear parasitaemia or
became positive again within 28 days after treatment. Recurring parasitaemia was related to age
(v
2 ¼ 4.8, P < 0.05) and parasite rates on admission (t ¼ 3.1, P < 0.01). PCR analysis showed that
some of these cases were novel infections. The adjusted recrudescence rate was 12.9% (95% CI 8.1–
17.7) overall, and 16.6% (95% CI 3.5–29.7), 15.5% (95% CI 8.3–22.7) and 6.9% (95% CI 0.4–13.4)
in three age groups (<5 years, 5–14, ‡15). The majority of infections carried mutations associated
with chloroquine resistance: 94% at pfcrt and 70% at pfmdr. Sp-resistant genotypes were also frequent:
99% and 73% of parasites carried two or more mutations at dhfr and dhps, respectively. The frequency
of alleles at dhfr, dhps and pfmdr was similar in cases that were successfully treated and those that
recrudesced.
conclusions The clinical trial showed that quinine 3-days combined to SP is still relatively effective
in the Chittagong Hill Tracts. However, if this regimen is continued to be widely used, further devel-
opment of SP resistance and reduced quinine sensitivity are to be expected. The genotyping results
suggest that neither chloroquine nor SP can be considered a reliable treatment for P. falciparum malaria
any longer in this area of Bangladesh.
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Introduction
In Bangladesh, malaria transmission is restricted to the
hilly districts in the eastern and northern border areas. The
majority of malaria cases are found in three districts of the
Chittagong Hill Tracts (CHT). The forested, green hills of
CHT are suitable breeding grounds for malaria vectors
from the Anopheles dirus complex. Malaria in this area is
of moderate endemicity, with perennial but seasonally
intense transmission (Rosenberg 1982). The Ministry of
Health statistics indicates that in 2001, 67% (37 180) of
the countrywide laboratory-conﬁrmed malaria cases oc-
curred in this area, which houses only 1% of the country’s
population. The CHT borders India and Myanmar and has
a large indigenous population of Chakma, Marma, Tripura
and other ethnic minorities. Health services in the
remote and rural areas of CHT were disrupted and are still
currently understaffed due to a preceding period of
political instability.
In 1999, Me ´decins sans Frontie `res (MSF-Holland) star-
ted two primary healthcare clinics (with laboratory facil-
ities) in a remote area of the CHT District Khagrachari.
Malaria is responsible for one-third of all disease cases
presenting to the clinics, with the predominant species
being Plasmodium falciparum. The nationally recommen-
ded ﬁrst line malaria treatment chloroquine (CQ) was
quickly abandoned in the MSF-H clinics due to an
unacceptably high number of treatment failures. This was
conﬁrmed in studies from other areas of Bangladesh
(Rahman et al. 1998, 2001) and bordering areas of
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(MSF-Holland, Assam, India, 2001, unpublished data).
Instead, P. falciparum patients were treated with the
national second line treatment, short course quinine (Q)
(3 days) followed by sulphadoxine/pyrimethamine on the
fourth day (SP; protocols described in Rahman et al. 1996;
Montanari et al. 2001). However, this treatment appears
to fail in some patients returning P. falciparum positive
within 1 month after treatment, suggesting that resistance
to its components Q and/or SP is arising. Indeed, resistance
to SP has been documented in Bangladesh (Government of
Bangladesh, unpublished report, 1993, quoted in Rahman
et al. 2001). Q 7-day therapy can result in parasitological
failures (Rahman et al. 2001). The efﬁcacy of the Q + SP
combination was last assessed in 1996–97 in Sadar
(Rahman et al. 1998) and Ramu (Rahman et al. 2001),
Cox’s Bazar District, and showed parasitological failure
rates of 80% and 66%, respectively. In this study, we
assessed the clinical efﬁcacy of Q + SP treatment in
P. falciparum patients in the CHT of Bangladesh.
We also assessed the status of P. falciparum resistance in
CHT by molecular investigation of infected blood samples
from the same patients. We genotyped the following
mutations in loci that are known to confer resistance to CQ,
Q and SP: (i) the point mutation K76T in the CQ resistance
transporter (Pfcrt) on chromosome 7, a major determinant
for both in vitro and in vivo CQ resistance (Fidock et al.
2000; Djimde et al. 2001); (ii) the N86Y mutation in
multidrug resistance gene pfmdr1 on chromosome 5 asso-
ciated with, but not essential for, CQ resistance (Foote et al.
1990); (iii) mutations in dihydrofolate reductase (dhfr)o n
chromosome 4 (51I, 59R, 108N, 164L), coding for a
stepwise increase in SP resistance; and (iv) mutations in
dihydropteroate synthase (dhps) on chromosome 8 (436A,
437G, 540E, 581G), known to further enhance SP resist-
ance (Plowe et al. 1998; Kublin et al. 2002).
Patients and methods
The study was performed from August to November 2002,
in the MSF-clinics of Baghaichara, Dighinala upazilla and
Pujgang, Panchari upazilla, situated at a distance of 25 km
from each other, in Khagrachari District near the Indian
border. The population within the catchment area, esti-
mated at 100 000, comprises a mix of indigenous and
Bengali people. The rainy season is from May to October.
The two MSF clinics were attended by a total of 57 000
patients from March 2000 till October 2002. About 60%
of these patients had fever or fever complaints and
therefore had their blood checked for malaria (by micro-
scopy). Forty-four per cent of all slides were positive, 84%
with P. falciparum mono-speciﬁc or mixed species infec-
tions, 15% P. vivax and 1% P. malariae. Infections were
distributed quite evenly across the population. During the
ﬁrst 9 months of 2002, we tested 15 268 patients and
found malaria infections in 42% of children under 5 years
(n ¼ 1805), in 48% of children 5–14 years old (n ¼ 2691)
and in 41% of adults 15 years and older (n ¼ 2189).
Around 46% of P. falciparum patients were females
(similar in the three age groups).
Patients were selected for the study according to the
following criteria: at least 1 year old, P. falciparum infec-
tion (mono or mixed) with more than 1000 asexual
malaria parasites microlitre, fever (axillary temperature of
37.5  C or higher) or a history of fever. Patients with a
parasitaemia higher than 100 000 but not above 250 000
parasites per microlitre were included only when no
additional general danger signs were present. Parasitaemia
of 250 000/ll (or 5% of red blood cells infected) was
considered a sign of severity and treated with parenteral
drugs in accordance with the national guidelines. Excluded
were pregnant women, patients with signs or symptoms of
severe malaria or with another febrile disease requiring
treatment. Patients ﬁtting these criteria and not living too
far from the clinic were given standard information on
the nature and purpose of the study. The patient was
included only after he/she (or their parent or caregiver)
gave verbal informed consent.
All patients received the same treatment: Q, three times
daily at 30 mg base/kg/day for 3 days followed by a single
dose of sulphadoxine (25 mg/kg) combined with pyri-
methamine (1.25 mg/kg) on the fourth day. Q adminis-
tration was semi-observed on a daily basis: one dose of Q
was taken in the clinic and two doses were given to take at
home, with comprehensive explanation before and ques-
tioning afterwards; SP treatment was given in the clinic
under observation.
The study procedures were based on WHO guidelines to
monitor antimalarial drug efﬁcacy (WHO 1996, 2002).
Patients were asked to return on day 3, 7, 14, 21 and 28,
and any other day when feeling ill. They were traced in
their homes when absent. Blood slides were collected at
each visit. If present, P. falciparum trophozoites were
counted using the parasite/white blood cell (WBC) count,
assuming a standard density of 8000 WBC/ll of blood.
Slide results were cross-checked by experienced malaria
microscopists of MSF and an external reference laboratory
(Chittagong Medical College Hospital). On days 0 and 14,
the haemoglobin value of the blood was checked with the
Lovibond-comparator method.
The efﬁcacy of treatment was evaluated by the patients’
parasitological response, and fever or fever complaints
were carefully recorded to give an indication of clinical
response. Cumulative failure rates were calculated at
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cation of early treatment failures, patients with moderate
levels of parasites in their blood (below 25% of that on day
of admission) on day 3 but no fever were not considered as
treatment failures. Patients with parasites in their blood
before day 7 and fever, as well as patients with parasitae-
mia at any day after day 7 irrespective of axillary
temperature, were retreated with Q 30 mg/kg/day for
7 days. Data were analysed with SPSS (SPSS Inc., Chicago,
IL, USA) and Epi Info (version 6; CDC, Atlanta, GA, USA).
Continuous data were analysed by t-test and proportions
were assessed by the chi-square test with Yates correction
or Fisher’s exact test.
The local community and authorities were informed on
the procedures of the study. Patients enrolled in the study
were given full clinical attention and treated according to
the usual protocols similar to regular clients; they came
back for follow-up visits entirely voluntarily but received a
small ﬁnancial incentive to compensate for travel-cost and
time lost.
Finger prick blood samples were collected on ﬁlter paper
(c.3 0ll) for genotyping by PCR from all patients at day 0
before taking treatment, and again in case of treatment
failure. Recurrent infections were identiﬁed by PCR ana-
lysis using methods described elsewhere (Brockman et al.
1999). For genotyping parasite mutations in drug resist-
ance genes, DNA was prepared from blood spots using the
Gentra systems extraction kit (Gentra Systems, Inc.,
Minneapolis, MN, USA). DNA extractions were concur-
rently prepared with plain Whatman paper discs to control
for contamination during DNA preparation: these samples
were also used as negative controls during PCR. We
genotyped the amino acid K76T mutation in pfcrt and the
N86Y mutation in pfmdr using a simple PCR restriction
digest assay and ﬂuorescent detection of products. We
ampliﬁed a 132-bp section of Pfcrt and a 216-bp section of
pfmdr using semi-nested PCR reactions, digested the PCR
products with ApoI, and measured the size of the digestion
products on an ABI 3100 capillary sequencer. DNA from
both CQ resistant (7G8) and sensitive (3D7) parasites was
used as positive controls (Anderson et al. 2003). For dhfr
and dhps, we used a rapid primer extension technique to
genotype all ﬁve mutations in each gene simultaneously
(Nair et al. 2002).
Results
During the period from August to October 2002, a total of
203 patients were enrolled in the study, 107 from Panchari
clinic and 96 from Dighinala clinic. The baseline character-
istics of the patients admitted to the study are shown in
Table 1.Theage/sexdistributionofthesegroupswassimilar
to the P. falciparum patients normally presenting to the two
clinics. In children (under 15 years), the parasitaemia at the
day of admission was signiﬁcantly higher than in the adult
group (t-test log-transformed parasite densities, t ¼ 2.5,
P < 0.05). The children in the age groups from 1 to <5 years
and 5 to 14 years also had signiﬁcantly higher body
temperaturesthan theadults(t-test: t ¼ 6.4,P < 0.001) and
lower haemoglobin values (t ¼ 6.9, P < 0.001).
Of 203 patients admitted to the study, 17 were lost
during follow-up (8.4%), 10 in Panchari and seven in
Dighinala. Altogether, 186 patients completed the study, of
whom only seven missed one visit.
Parasitological response
The crude parasitological failure rate was 17.2% at day 28
(Table 2). Dighinala and Panchari clinics showed similar
results. Failures were related to parasitaemia on admission
(t-test: t ¼ 3.1, P < 0.01); the geometric mean parasitae-
mia of infections for which treatment failed was 17 677
parasites/ll vs. 12 210 parasites/ll in successfully treated
cases. The risk of treatment failure in patients with a
density over 100 000 parasites/ll( n ¼ 7) was signiﬁcantly
higher than in patients with a lower parasitaemia [57% vs.
16%, RR ¼ 3.63 (95% CI 1.76–7.51)]. Younger infants
and children were found to be more at risk of P. falcipa-
Table 1 Baseline characteristics of patients admitted to the study
<5 years 5–14 years ‡15 years Total
Number of patients 34 103 66 203
Sex: number of F/M (% F) 13/20 (39) 41/62 (40) 27/39 (41) 81/122 (40)
Age (years)* 2.8 (1–4.5) 8.7 (5–14) 24.8 (15–72) 13.1 (1–72)
Weight (kg)* 11.5 ± 2.2 (7.5–16.0) 22.7 ± 8.3 (12–50) 47.4 ± 6.9 (29–75.0) 28.8 ± 15.2 (7.5–75)
Haemoglobin (g/dl)* 9.5 ± 1.9 (5.3–11.7) 11.1 ± 1.8 (6.7–16.7) 12.7 ± 2.0 (6.7–16.7) 11.3 ± 2.2 (5.3–16.7)
Temperature ( C)* 38.0 ± 1.1 (36.4–40.0) 38.1 ± 1.2 (35.6–40.6) 36.9 ± 0.9 (35.0–39.6) 37.7 (35–40.6)
Parasite density (per ll) 17 501 (1236–135 944) 14 328 (963–255 250) 9414 (1043–87 553) 12 965 (963–255 250)
* Values are given as mean ± SD (range).
 Values representing geometric mean (range).
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failure rates at day 14 were signiﬁcantly higher in infants
than in older children [RR ¼ 7.97 (1.62–39.1), v
2 ¼ 9.2,
P < 0.01] and in the adult group [RR ¼ 9.38 (1.14–76.9),
v
2 ¼ 6.7, P < 0.01]. Furthermore, at day 28 the failure
rate was higher in infants than in adults [RR ¼ 2.99 (1.07–
8.37), v
2 ¼ 4.8, P < 0.05].
During follow-up, 16 of 186 patients (9%) developed
P. vivaxinfections(atdays21–28).Exceptfortheonemixed
Pf/Pv infection, these patients were treated with CQ. They
werekeptinthestudygroup,buttheCQmayhaveinterfered
with the outcome of their follow-up, as none failed.
PCR-corrected response
Genotyping of 101 blood samples with P. falciparum
infections yielded 132 genotypes, reﬂecting a wide degree
of genetic diversity in the parasite population, based on the
three gene loci examined (merozoite surface proteins-1 and
-2, and glutamate rich protein). The average number of
P. falciparum genotypes per infection was 1.3. The most
common genotype was recorded in six of 132 genotypes,
giving a probability of detecting the same genotype both
pre- and post-treatment by chance alone of 0.045. This
justiﬁed the assumption that identical three-locus geno-
types occurring pre- and post-treatment in the same patient
must be recrudescent.
Of the 32 patients who returned with a P. falciparum
infection, 28 paired samples were collected. Of these 28
samples, six failed to produce a result due to inability to
amplify DNA in the post-treatment sample. The results of
the 22 remaining samples showed eight novel infections
and 14 recrudescent infections. Table 2 shows the PCR-
corrected day 28 cumulative failure rates, assuming that
samples without PCR results were failures. Corrected
failure rates no longer showed a signiﬁcant difference
among age groups.
The parasite and gametocyte rates during the time of
follow-up are shown in Figure 1. At day 3 after treatment,
14 patients (7.3%) still had parasitaemia, but only one
patient had fever, and was therefore classiﬁed as a failure
and retreated. The other 13 all cleared their parasites by
day 7 without additional treatment. Within 4 weeks, 31
patients became positive for P. falciparum, with eight of
186 PCR-conﬁrmed novel infections (4%).
Gametocytes were found in few patients at admission
(6.2%). During follow-up, another 53 patients (28%) had
gametocytes in their blood at one or more follow-up visits.
The gametocyte rate rose at days 3 and 7 to 21%, but
declined after that (Figure 1).
Clinical response
Of all 32 failures (in 186 cases), 17 cases had fever or a
history of fever and were categorized as clinical failures:
one early clinical failure (0.5%) and 16 late clinical failures
(8.6%), and the remaining 15 cases were late parasitolog-
ical failures (8.1%).
The mean (SD) haemoglobin values showed a small
increase after treatment: from 11.3 (2.2) g/dl at day 0 to
11.7 (1.6) g/dl at day 14. There was no clear difference
Table 2 Assessment of quinine–sulphadoxine/pyrimethamine treatment failure rate
<5 years 5 to <15 years ‡15 years Total
n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI)
Number of patients 34 103 66 203
Dropout 3 8.8 6 5.8 8 12.1 17 8.4
Failure rate day 14 5/32 15.6 (3.0–28.2) 2/102 2.0 (0–4.7) 1/60 1.7 (0–5.0) 8/194 4.1 (1.3–6.9)
Failure rate day 28 8/31 25.8 (21.0–41.2) 19/97 19.6 (11.7–27.5) 5/58 8.6 (1.4–15.8) 32/186 17.2 (11.8–22.6)
PCR corrected day 28* 5/31 16.6 (3.5–29.7) 15/97 15.5 (8.3–22.7) 4/58 6.9 (0.4–13.4) 24/186 12.9 (8.1–17.7)
* Missing PCR data indicate failures.
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Figure 1 Parasitological and gametocidal response during
4 weeks after quinine–sulphadoxine/pyrimethamine treatment.
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ment failures and those without.
Patients complained mainly of mild symptoms, such as
dizziness, headache, nausea, itching, which may have been
an effect of the treatment and disease alike. Three patients
reported loss of hearing. One patient had an allergic reac-
tion to Q: a few large bluish-black patches (drug eruptions)
appeared symmetrically on arms and legs at day 2 of Q
treatment but no other signs of allergy were seen and the
patches disappeared after Q treatment was stopped.
Twenty patients received additional non-malaria treatment
for diseases diagnosed during the follow-up period (respir-
atory tract infections, ear infection, eye infection, worms).
Drug resistance markers
Of the 203 samples, three were not genotyped for dhfr,
while four, ﬁve and 16 samples were not genotyped for
pfcrt, dhps and pfmdr, respectively. Low levels of multiple
infections were observed: 12 of 199 samples (6%) carried
multiple genotypes at pfcrt, 14 of 187 (7%) had multiple
infections at pfmdr, while 18 of 200 (9%) and 22 of 198
(11%) had multiple bases present in at least one of the ﬁve
sites in dhfr and dhps. We analysed only infections carrying
single alleles for each locus.
The prevalence of the CQ resistance-related Pfcrt and
Pfmdr mutant alleles was particularly high: 94% of para-
sites(176/187)carriedthe76Tmutationatpfcrt,while70%
(121/173) carried the 86Y mutation at pfmdr. In addition,
key mutations for SP resistance at dhfr and dhps were very
common. At dhfr, six different alleles were identiﬁed: no
parasites contained sensitive, wild-type dhfr alleles, 1%
(1/182) had a single resistance mutation, whereas 74%
(135/182) had double mutations, 25% (45/182) triple
mutations and 1% (1/182) quadruple mutations. The
mutation 164L, which results in high-level resistance to
pyrimethamine, was found in 7% of cases (12/186). Eight
dhps alleles were identiﬁed: 5% (9/176) of parasites were
wild type, 22% (39/176) had one mutation and 36%
(62/176) had two mutations, while 38% (66/176) had
three mutations. The genotype data are summarized in
Table 3(a).
Table 3 Allele frequencies of mutations in
dhfr, dhps, pfcrt and pfmdr: (a) of all
samples analysed and (b) of samples from
patients with known outcome of treatment,
i.e. ‘sensitive’ or ‘recrudescent’ infections
(a) Result of samples of all patients
(n ¼ 203)*
(b) Result related to clinical
response to Q + SP
Amino acids Count Frequency
Sensitive
(n ¼ 162)*
Recrudescent
(n ¼ 16)*
DHFR AIRNL 1 0.01 0.01 0
AIRNI 34 0.19 0.15 0.20
AICNI 5 0.03 0.03 0.07
ANRNI 130 0.71 0.74 0.67
ANRNL 11 0.06 0.07 0.07
ANCNI 1 0.01 0.01 0
ANCSI 0 0 0 0
DHPS SGEGA 2 0.01 0.01 0
AGEAA 64 0.36 0.39 0.15
SGKGA 45 0.26 0.22 0.46
AGKAA 4 0.02 0.02 0
SGEAA 12 0.07 0.05 0.23
AAEAA 1 0.01 0.01 0
SGKAA 39 0.22 0.25 0.15
SAKAA 9 0.05 0.05 0
PfCRT-76 T 176 0.94 0.95 0.93
K 11 0.06 0.05 0.07
PfMDR-86 Y 121 0.70 0.73 0.57
N 52 0.30 0.27 0.43
* Total numbers are given above, but numbers genotyped for each locus may be lower
(see text).
 The ﬁve letter codes for dhfr show amino acid residues at positions 16, 51, 59, 108 and
164, while codes for dhps show amino acids at positions 436, 437, 540, 581 and 613,
respectively. Amino acids conferring resistance are shown in bold italic. Alleles are listed in
order of decreasing resistance.
 Counts and frequencies are based only on samples with single alleles, multiple infections
were excluded from analyses.
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to Q–SP therapy
There were 32 patients who had a P. falciparum infection
in the follow-up period and 154 who remained negative
following treatment. We were able to identify eight novel
and 14 recrudescent infections by PCR analysis. Another
two early failures at days 3 and 7 are presumed recrudes-
cent as well. This divides the patients in two groups: 162
‘sensitive’ infections (treatment success or coming back
with new infection) and 16 ‘recrudescent’ ones (identiﬁed
by PCR or early failure).
The Q–SP recrudescent strains all had multiple muta-
tions at dhfr and one or more mutations at the dhps site.
However, the frequency of the various allele combinations
found in dhfr, dhps, pfcrt and pfmdr sites did not differ
signiﬁcantly between sensitive and recrudescent infections
(Table 3b). Presumed SP refractory genotypes with triple
or quadruple mutations in dhfr were not more frequent in
the recrudescent infections (31%, 4/13) than the sensitive
ones (23%, 33/145; Fisher’s exact test, two-tailed,
P ¼ 0.50), neither were the SP resistance-enhancing double
or triple mutations at dhps, which were found in 83%
(10/12) of recrudescent and in 70% (99/141) of sensitive
strains (Fisher’s exact test, P ¼ 0.51). Even in the more
vulnerable groups, young children and patients with high-
density infections, we could not ﬁnd a relationship between
the molecular markers of resistance in dhfr and dhps and
treatment failures. Gametocytaemia at any day during the
follow-up period, known to be enhanced by dhfr and dhps
mutations (Mendez et al. 2002), also appeared unrelated to
the number of mutations at these loci (dhfr single or double
vs. more than two mutations: v
2 ¼ 1.76, P ¼ 0.18; dhps
wild type or single mutations vs. two or three mutations:
v
2 ¼ 1.18, P ¼ 0.27).
Discussion
The genotyping of isolates from the 203 patients’ pre-
treatment blood samples showed that the majority of
patients had a genetically CQ-resistant P. falciparum
infection: 94% had the 76T mutation in pfcrt and 70%
86Y at pfmdr1. High prevalence of pfcrt mutations has
been reported from various South-east Asian countries,
whereas pfmdr mutation rate is generally lower than what
was found here (Labbe et al. 2001; Berens et al. 2003;
Ngo et al. 2003; Pickard et al. 2003). Patients carrying
parasites with the 76T pfcrt mutation have a 30–50%
chance of CQ treatment failure, and probably even more
when the 86Y pfmdr mutation is also present (Djimde
et al. 2001; Jelinek et al. 2002). This is consistent with
the high in vitro and in vivo CQ resistance reported in
Bangladesh (Rahman et al. 1998, 2001; Noedl et al.
2003).
At present CQ is still used as a ﬁrst line antimalarial in
many treatment facilities in Bangladesh. The large group of
patients returning for second line treatment normally
receives short course Q + SP combination therapy. Our
results show that the Q + SP combination treatment for
P. falciparum malaria patients is still relatively effective in
the CHT of Bangladesh. The failure rate in this 28-day
follow-up survey was 12.9% when new infections identi-
ﬁed with PCR were taken into account. Nevertheless, there
are several reasons for concern when Q + SP therapy is
continued to be used as common second line treatment in
Bangladesh.
First, parasites in this region have clearly developed
resistance to SP. In Bangladesh resistance to SP has been
documented previously (in unpublished data, Government
of Bangladesh 1993, quoted in Rahman et al. 2001). The
genotyping data reported here indicate that resistant alleles
at both dhps and dhfr have spread to Bangladesh as a result
of SP use, as recently described for other SE Asian countries
(Nair et al. 2003; Ngo et al. 2003). Single or double
mutant dhfr generally have increased parasite clearance
times and higher post-treatment gametocyte carriage than
wild-type parasites, while parasites with three or four
resistance mutations are refractory to SP treatment.
Mutations in dhps play a limited role on their own, but in
the presence of mutations in dhfr, resistance to SP is
enhanced (Plowe et al. 1998; Kublin et al. 2002). Hence,
we can expect that at least the quarter of the parasite
population that shows triple or quadruple mutations in
dhfr will not respond adequately to SP treatment, in
particular the 20% also carrying one or more mutations at
dhps. Another factor contributing to the rapid spread of
antifolate resistance is the high level of gametocytes after
SP treatment. Gametocytaemia is enhanced by SP and this
might increase malaria transmission and promote the
spread of drug resistance (von Seidlein et al. 2001; Mendez
et al. 2002). In our clinical trial on Q–SP efﬁcacy,
SP-resistant genotypes were not more frequently observed
in recrudescent than in sensitive infections, although
the differences were in the predicted direction. This
suggests that failures of this therapy may not result from
SP resistance alone.
Secondly, the Q short course (3 days) component of the
Q–SP combination therapy may be insufﬁciently effective.
So far, no clinical failures from Q (7 days) were found in
Bangladesh, but parasitological failures have been reported
(Rahman et al. 2001), as well as a low level of in vitro
resistance to Q (Noedl et al. 2003). Hence, Q resistance
may also contribute to the patterns observed. Furthermore,
SP-resistant P. falciparum strains may not be adequately
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slow-acting drug and therefore unable to kill most parasites
in 3 days (White 1998). Moreover, some patients may not
have complied with the complete Q treatment, because we
were only able to give one of the three daily doses under
observation in the clinic.
Thirdly, children and patients with high parasitaemia are
at increased risk of failure from Q + SP treatment. We
found that the proportion of children with parasites in the
blood within 28 days after treatment is higher than that of
adults, which is attributable to recrudescent and novel
infections. Treatment failures were related to higher
parasite densities. Patients with a parasitaemia above
100 000/ll appeared to be at a much higher risk of failure.
The parasite rates in children (up to 15 years) were
generally higher than in the adults.
Fourthly, the actual percentage of patients with recurring
infections after Q + SP treatment may be higher than
indicated in our 28-day study. Failures from SP can occur
4–6 weeks after treatment (Mabuza et al. 2001). Higher
failure rates of Q + SP treatment than our study have been
documentedinBangladesh,Cox’sBazarDistrict,previously.
Crude parasitological failure rates of 20% were observed in
a 14-day assessment (Rahman et al. 1998) and 34% in a
28-day assessment (Rahman et al. 2001), without PCR
analyses to distinguish novel and recrudescent infections. In
our study, the crude parasitological failure rate at day 28
was17%.PCRanalysesidentiﬁedone-fourth ofrecurrences
as‘novel’infections. However,thereremains apossibility of
underestimating the true recrudescence rate if a post-
treatment strain was present but not ampliﬁed in the pre-
treatment sample, which can occur if the density was below
the limit of PCR detectability (Brockman et al. 1999).
We suggest a change in malaria treatment protocols in
the CHT region of Bangladesh. Artemisinin combination
therapy is now advocated by WHO and the worldwide
scientiﬁc malaria community and is the aim for all MSF
projects in P. falciparum endemic areas. Combination
therapies including artemisinin or its derivatives have
proven to be excellent drugs for the treatment of malaria.
These drugs also reduce post-treatment levels of gameto-
cytes, thereby reducing transmission and protecting partner
drugs from developing resistance. The radical treatment
and reduced transmission by artemisinin have shown to
substantially reduce the incidence of malaria (Price et al.
1996; White 1998; White et al. 1999; Nosten et al. 2000).
We predict that combination therapies including artemis-
inin derivatives would result in improved treatment efﬁc-
acy and decreased mortality of P. falciparum infected
patients in the CHT region of Bangladesh. However,
combinations with SP should not be adopted, as levels of
resistance to these drugs are already high.
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